Head-To-Head Contrast: Gene Biotherapeutics (OTCMKTS:CRXM) vs. Editas Medicine (OTCMKTS:EDIT)

Gene Biotherapeutics (OTCMKTS:CRXM) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

79.7% of Editas Medicine shares are held by institutional investors. 49.8% of Gene Biotherapeutics shares are held by insiders. Comparatively, 0.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Gene Biotherapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares Gene Biotherapeutics and Editas Medicine’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gene Biotherapeutics N/A N/A -$2.91 million N/A N/A
Editas Medicine $31.94 million 37.30 -$109.95 million ($2.33) -10.33

Gene Biotherapeutics has higher earnings, but lower revenue than Editas Medicine.

Analyst Ratings

This is a summary of recent recommendations for Gene Biotherapeutics and Editas Medicine, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gene Biotherapeutics 0 0 0 0 N/A
Editas Medicine 0 4 6 0 2.60

Editas Medicine has a consensus target price of $38.50, indicating a potential upside of 60.02%. Given Editas Medicine’s higher possible upside, analysts clearly believe Editas Medicine is more favorable than Gene Biotherapeutics.


This table compares Gene Biotherapeutics and Editas Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gene Biotherapeutics N/A N/A N/A
Editas Medicine -412.70% -47.46% -26.79%

About Gene Biotherapeutics

Taxus Cardium Pharmaceuticals Group, Inc. manages a portfolio of medical technologies in the United States. The company engages in the development and commercialization of Generx, an angiogenic gene therapy product candidate that is in Phase III clinical trial for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It also provides Excellagen technology platform, a FDA-approved flowable dermal matrix for advanced wound care treatment, as well as serves as a delivery platform for small molecule drugs, proteins, and biologics. In addition, the company develops a medical data analytics technology platform, which offers products for the life insurance and healthcare sectors. The company was formerly known as Cardium Therapeutics, Inc. and changed its name to Taxus Cardium Pharmaceuticals Group, Inc. in March 2014. Taxus Cardium Pharmaceuticals Group, Inc. was founded in 2003 and is headquartered in San Diego, California.

About Editas Medicine

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Gene Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gene Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.